Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1616392 | 0.81 | ACHE (0.47) | ACHEBCHE | |
| SCHEMBL30584471 | 0.81 | CA12 (0.41) | ACHEBCHE | |
| SCHEMBL7333093 | 0.81 | CA12 (0.41) | ACHEBCHE | |
| SCHEMBL24713686 | 0.77 | — | — | |
| SCHEMBL30186190 | 0.76 | ALDH1A1 (0.32) | — | |
| SCHEMBL9813616 | 0.75 | LMNA (0.48) | ACHEBCHE | |
| SCHEMBL19390301 | 0.75 | ACHE (0.33) | ACHE | |
| SCHEMBL2240708 | 0.74 | ACHE (0.45) | ACHEBCHE | |
| SCHEMBL28261346 | 0.74 | ALDH1A1 (0.47) | — | |
| SCHEMBL23730279 | 0.74 | KDM4E (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345665-B2 | Chiral 1,3-diarylimidazolium salt carbene precursor, synthesis method therefor, metal salt compound and application thereof | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2022-05-31 | — | — | US | disclosed |
| US-20200369620-A1 | CHIRAL 1,3-DIARYLIMIDAZOLIUM SALT CARBENE PRECURSOR, SYNTHESIS METHOD THEREFOR, METAL SALT COMPOUND AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2020-11-26 | — | — | US | disclosed |
| WO-2010150913-A1 | INK FOR INKJET RECORDING, INKJET RECORDING METHOD USING THE SAME, INK CARTRIDGE HOUSING THE SAME, AND RECORDED MATTER | RICOH COMPANY, LTD. (JP) | 2010-12-29 | — | — | WO | disclosed |
| WO-2009109992-A1 | NOVEL PROCESS FOR PREPARATION OF DULOXETINE AND INTERMEDIATES FOR USE THEREIN | ARCH PHARMALABS LIMITED (IN) | 2009-09-11 | — | — | WO | disclosed |
| EP-0835107-A1 | THE USE OF ALPHA-1C-SELECTIVE ADRENOCEPTOR AGONISTS FOR THE TREATMENT OF URINARY INCONTINENCE | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1998-04-15 | — | — | EP | disclosed |
| US-5610174-A | Use of α1A -selective adrenoceptor agonists for the treatment of urinary incontinence | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1997-03-11 | — | — | US | disclosed |
| WO-1996038143-A1 | THE USE OF ALPHA-1C-SELECTIVE ADRENOCEPTOR AGONISTS FOR THE TREATMENT OF URINARY INCONTINENCE | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1996-12-05 | — | — | WO | disclosed |
| EP-0150192-B1 | BICYCLIC BENZENOID AMINOALKYLENE ETHERS AND THIOETHERS | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1989-12-20 | — | — | EP | disclosed |
| US-4745110-A | ANTIULCER AGENTS, ANTISECRETORY AGENTS | RORER PHARMACEUTICAL CORPORATION (US) | 1988-05-17 | — | — | US | disclosed |
| US-4692445-A | ANTISECRETORY, ANTIULCEROGENIC AGENTS | RORER PHARMACEUTICAL CORPORATION (US) | 1987-09-08 | — | — | US | disclosed |
| US-4647559-A | ANTISECRETORY AND ANTIULCER AGENTS | WILLIAM H. RORER, INC. (US) | 1987-03-03 | — | — | US | disclosed |
| US-4638001-A | ANTISECRETORY, ANTIULCER AGENTS | WILLIAM H. RORER, INC. (US) | 1987-01-20 | — | — | US | disclosed |
| US-4588719-A | ANTISCERETORY AGENTS, ANTIULCER AGENTS | WILLIAM H. RORER, INC. (US) | 1986-05-13 | — | — | US | disclosed |
| EP-0150192-A4 | BICYCLIC BENZENOID AMINOALKYLENE ETHERS AND THIOETHERS. | RORER INTERNAT OVERSEAS INC (US) | 1985-09-16 | — | — | EP | disclosed |
| EP-0150192-A1 | BICYCLIC BENZENOID AMINOALKYLENE ETHERS AND THIOETHERS. | RORER INT OVERSEAS (US) | 1985-08-07 | — | — | EP | disclosed |
| US-4529723-A | Gastrointestinal disorders; antiulcer agents | WILLIAM H. RORER, INC. (US) | 1985-07-16 | — | — | US | disclosed |
| WO-1984004247-A1 | BICYCLIC BENZENOID AMINOALKYLENE ETHERS AND THIOETHERS, AND THEIR PHARMACEUTICAL USES | RORER INT OVERSEAS (US) | 1984-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369620-A1 | CHIRAL 1,3-DIARYLIMIDAZOLIUM SALT CARBENE PRECURSOR, SYNTHESIS METHOD THEREFOR, METAL SALT COMPOUND AND APPLICATION THEREOF | CYP51A1, SLC39A11, ZC3HAV1L | ACHE 3609/4885BCHE 1020/4885 |
| US-11345665-B2 | Chiral 1,3-diarylimidazolium salt carbene precursor, synthesis method therefor, metal salt compound and application thereof | CYP51A1, SLC39A11, ZC3HAV1L | ACHE 3609/4885BCHE 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.